Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to solve genetically complex problems. The company is headquartered in Menlo Park, California.
| Revenue (TTM) | $159.27M |
| Gross Profit (TTM) | $46.86M |
| EBITDA | $199.18M |
| Operating Margin | -114.40% |
| Return on Equity | -929.00% |
| Return on Assets | -14.10% |
| Revenue/Share (TTM) | $0.52 |
| Book Value | $-0.11 |
| Price-to-Book | 170.66 |
| Price-to-Sales (TTM) | 2.36 |
| EV/Revenue | 5.2 |
| EV/EBITDA | 140.79 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -1.90% |
| Shares Outstanding | $310.83M |
| Float | $304.06M |
| % Insiders | 8.92% |
| % Institutions | 55.28% |
Volatility is currently expanding
PACB cuts its 2026 revenue outlook after Q2 sales fall 2%, as consumables and EMEA growth fail to offset weaker instruments and Asia-Pacific.
Pacific Biosciences reported Q2 revenues of $39.01 million, missing estimates and guiding 2026 revenues down, below consensus. Operating and net losses remain sizable, with cash now under $237 million and nearly $645 million in debt outstanding. PACB trades at 2.4x expected 2026 revenues, a steep discount to peers, reflecting weaker financials and growth prospects.
Pacific Biosciences of California, Inc. (PACB) Q2 2026 Earnings Call Transcript
Pacific Biosciences of California NASDAQ: PACB reported second-quarter 2026 revenue of $39 million, roughly flat from $39.8 million a year earlier, while announcing an immediate leadership transition and lowering its full-year revenue outlook amid a slower-than-expected rollout of its new multi-use sequencing chemistry and continued funding constraints in academic and government markets.
Christian Henry to Transition from President and Chief Executive Officer Following Six Years of Leadership; Effective August 5, 2026 Christian Henry to Transition from President and Chief Executive Officer Following Six Years of Leadership; Effective August 5, 2026
MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2026.
Vega SPRQ-Nx chemistry to deliver up to 90 Gb per run at 40% lower cost per gigabase, with single-shift runs and new workflow controls for regulated labs Vega SPRQ-Nx chemistry to deliver up to 90 Gb per run at 40% lower cost per gigabase, with single-shift runs and new workflow controls for regulated labs
McKesson, Cencora, Solventum and PacBio head into earnings with resilient demand offset by tariffs, funding pressure and pricing challenges.
MENLO PARK, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, at 9:00 AM ET in Boston, Massachusetts.
In the most recent trading session, Pacific Biosciences of California (PACB) closed at $1.36, indicating a -5.56% shift from the previous trading day.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PACB and any ticker you trade — then tracks every position and per-strategy win rate.
